Cargando…

Entecavir-associated thrombocytopenia

Entecavir (ETV) is widely used in the treatment of hepatitis B, but there are only a few reports about entecavir-associated thrombocytopenia, and it is considered as an immediate response and inappropriate to continue the treatment with other nucleoside analogues. Now, we report the third case, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yi, Feng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674478/
https://www.ncbi.nlm.nih.gov/pubmed/34823407
http://dx.doi.org/10.1177/20587384211059676
_version_ 1784615663882469376
author Yu, Yi
Feng, Hao
author_facet Yu, Yi
Feng, Hao
author_sort Yu, Yi
collection PubMed
description Entecavir (ETV) is widely used in the treatment of hepatitis B, but there are only a few reports about entecavir-associated thrombocytopenia, and it is considered as an immediate response and inappropriate to continue the treatment with other nucleoside analogues. Now, we report the third case, and this case was delayed response and we switched to treatment with tenofovir (TDF). There was a 66-year-old female who was infected with hepatitis B virus (HBV). Her platelet count decreased from 111*10(9)/L to 3*10(9)/L and was prone to gum bleeding and skin ecchymosis after she received ETV treatment for 88 days. As a treatment option, ETV was replaced by TDF immediately, frequent platelets transfusions and thrombopoietin were applied for several days, daily prednisone of 50 mg was concomitantly taken, and then platelet count improved after 10 days. She was diagnosed with entecavir-associated thrombocytopenia after analysis of the temporal relationship and exclusion of other causes of thrombocytopenia by blood and bone marrow examinations. Our case suggested that the platelet count should be monitored regularly in patients during ETV treatment, and it may be a feasible option to choose TDF to maintain antiviral treatment when entecavir-associated thrombocytopenia occurs.
format Online
Article
Text
id pubmed-8674478
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86744782021-12-17 Entecavir-associated thrombocytopenia Yu, Yi Feng, Hao Int J Immunopathol Pharmacol Case Report Entecavir (ETV) is widely used in the treatment of hepatitis B, but there are only a few reports about entecavir-associated thrombocytopenia, and it is considered as an immediate response and inappropriate to continue the treatment with other nucleoside analogues. Now, we report the third case, and this case was delayed response and we switched to treatment with tenofovir (TDF). There was a 66-year-old female who was infected with hepatitis B virus (HBV). Her platelet count decreased from 111*10(9)/L to 3*10(9)/L and was prone to gum bleeding and skin ecchymosis after she received ETV treatment for 88 days. As a treatment option, ETV was replaced by TDF immediately, frequent platelets transfusions and thrombopoietin were applied for several days, daily prednisone of 50 mg was concomitantly taken, and then platelet count improved after 10 days. She was diagnosed with entecavir-associated thrombocytopenia after analysis of the temporal relationship and exclusion of other causes of thrombocytopenia by blood and bone marrow examinations. Our case suggested that the platelet count should be monitored regularly in patients during ETV treatment, and it may be a feasible option to choose TDF to maintain antiviral treatment when entecavir-associated thrombocytopenia occurs. SAGE Publications 2021-11-25 /pmc/articles/PMC8674478/ /pubmed/34823407 http://dx.doi.org/10.1177/20587384211059676 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Yu, Yi
Feng, Hao
Entecavir-associated thrombocytopenia
title Entecavir-associated thrombocytopenia
title_full Entecavir-associated thrombocytopenia
title_fullStr Entecavir-associated thrombocytopenia
title_full_unstemmed Entecavir-associated thrombocytopenia
title_short Entecavir-associated thrombocytopenia
title_sort entecavir-associated thrombocytopenia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674478/
https://www.ncbi.nlm.nih.gov/pubmed/34823407
http://dx.doi.org/10.1177/20587384211059676
work_keys_str_mv AT yuyi entecavirassociatedthrombocytopenia
AT fenghao entecavirassociatedthrombocytopenia